Literature DB >> 11015972

ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants.

M Schiffman1, M E Adrianza.   

Abstract

OBJECTIVE: To describe the design and methods of the ASCUS-LSIL Triage Study (ALTS), a multicenter, randomized clinical trial designed to evaluate three alternative methods of managing low grade (LSIL) and equivocal (ASCUS) cervical cytologic diagnoses. STUDY
DESIGN: Nonpregnant women, 18+ years old, with ASCUS or LSIL, no prior hysterectomy or ablative therapy to the cervix, were referred to one of four clinical centers around the United States. Eligible and consenting participants were administered a risk-factor questionnaire and underwent a pelvic examination, collection of cervical specimens for liquid-based cytology and human papillomavirus (HPV) testing and Cervicography (National Testing Laboratories, Fenton, Missouri, U.S.A.). Patients were randomized to one of three arms: (1) immediate referral for colposcopy at enrollment, (2) follow-up with cytology only, and (3) use of HPV DNA testing to triage to colposcopy. All women are followed every six months for two years with pelvic examinations, cytologic and masked HPV testing, and masked Cervicography. Digital cervical images and cytology and histology slides are externally reviewed to maximize patient safety.
RESULTS: We enrolled and randomized 3,488 eligible women with ASCUS and 1,572 women with LSIL.
CONCLUSION: The successful enrollment, randomization and high rates of follow-up are encouraging. The study will help clarify the optimal strategies for managing low grade cervical abnormalities.

Entities:  

Mesh:

Year:  2000        PMID: 11015972     DOI: 10.1159/000328554

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  67 in total

1.  HPV testing for clarifying borderline cervical smear results.

Authors:  M M Manos
Journal:  BMJ       Date:  2001-04-14

2.  Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.

Authors:  Morgan A Marks; Philip E Castle; Mark Schiffman; Patti E Gravitt
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.

Authors:  Philip E Castle; Erin C Gutierrez; Sharon V Leitch; Courtney E Maus; Ray A McMillian; William A Nussbaumer; Laurence M Vaughan; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

4.  Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.

Authors:  Nicole G Campos; Philip E Castle; Mark Schiffman; Jane J Kim
Journal:  Med Decis Making       Date:  2011-12-06       Impact factor: 2.583

5.  Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Zoe R Edelstein; Ayaka Hulbert; Mark Schiffman; Nancy B Kiviat
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

6.  Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; Zhonghu He; Rachel L Winer; Ayaka Hulbert; Shu-Kuang Lee; Yang Ke; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2012-07-11       Impact factor: 7.396

7.  Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.

Authors:  Clara Bodelon; Svetlana Vinokurova; Joshua N Sampson; Johan A den Boon; Joan L Walker; Mark A Horswill; Keegan Korthauer; Mark Schiffman; Mark E Sherman; Rosemary E Zuna; Jason Mitchell; Xijun Zhang; Joseph F Boland; Anil K Chaturvedi; S Terence Dunn; Michael A Newton; Paul Ahlquist; Sophia S Wang; Nicolas Wentzensen
Journal:  Carcinogenesis       Date:  2015-12-09       Impact factor: 4.944

8.  Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.

Authors:  Long Fu Xi; Laura A Koutsky; Philip E Castle; Cosette M Wheeler; Denise A Galloway; Constance Mao; Jesse Ho; Nancy B Kiviat
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

9.  Impact of improved classification on the association of human papillomavirus with cervical precancer.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Am J Epidemiol       Date:  2009-12-10       Impact factor: 4.897

10.  Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study.

Authors:  Philip E Castle; Patti E Gravitt; Diane Solomon; Cosette M Wheeler; Mark Schiffman
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.